<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00959218</url>
  </required_header>
  <id_info>
    <org_study_id>cnp-MS-0601 / MC-2006-01</org_study_id>
    <nct_id>NCT00959218</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of the Pain Relieving Effect of Dronabinol in Central Neuropathic Pain Related to Multiple Sclerosis</brief_title>
  <official_title>Multi-centre, Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of the Pain Relieving Effect of Dronabinol in Patients With Multiple Sclerosis Associated With Central Neuropathic Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bionorica Research GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bionorica Research GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether Dronabinol is effective and safe in
      relieving central neuropathic pain in multiple sclerosis patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multiple sclerosis (MS) is in all probability an autoimmune disease causing severe
      neurological disability due to inflammation and degeneration in the central nervous system
      (CNS). MS affects over 1 million people worldwide. Central neuropathic pain is associated
      with approximately 30% of all patients with MS. MS-accompanying pain has a major impact on
      the patients' quality of life as usual conventional analgesics are little effective. The aim
      of this clinical study is to determine whether Dronabinol is effective and safe in relieving
      central neuropathic pain in multiple sclerosis patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change of baseline pain severity score on the 11-point Likert Numerical Rating Scale recorded in patient diary</measure>
    <time_frame>max. 2.5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Likert Numerical Rating Scale pain relief</measure>
    <time_frame>max. 2.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain-related sleep interference</measure>
    <time_frame>max. 2.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SF-36 (QoL-questionnaire)</measure>
    <time_frame>max. 2.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intake of rescue medication</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">240</enrollment>
  <condition>Central Neuropathic Pain in Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Dronabinol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dronabinol</intervention_name>
    <description>oral solution, daily dose up to 15 mg, treatment up to 2.5 years</description>
    <arm_group_label>Dronabinol</arm_group_label>
    <other_name>(-)trans-delta9-tetrahydrocannabinol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>oral solution</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of multiple sclerosis acc. to McDonald diagnostic criteria

          -  EDSS score between 3 and 8 (incl.)

          -  Patients who are in a stable phase of multiple sclerosis

          -  Patients with MS-related central neuropathic pain for at least 3 months

        Exclusion Criteria:

          -  Severe concomitant diseases

          -  Certain concomitant therapies (in particular: pain influencing concomitant therapies)

          -  Dronabinol intake within the last 12 months prior to study entry or Marihuana use
             within one month prior to study entry
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sebastian Schimrigk, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinikum Luedenscheid</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Maerkische Kliniken GmbH, Klinikum Luedenscheid, Akademisches Lehrkrankenhaus der Universitaet Bonn, Klinik fuer Neurologie</name>
      <address>
        <city>Luedenscheid</city>
        <zip>58515</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 13, 2009</study_first_submitted>
  <study_first_submitted_qc>August 13, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 14, 2009</study_first_posted>
  <last_update_submitted>February 2, 2012</last_update_submitted>
  <last_update_submitted_qc>February 2, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 3, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dronabinol</keyword>
  <keyword>(-)trans-delta9-tetrahydrocannabinol</keyword>
  <keyword>central neuropathic pain</keyword>
  <keyword>multiple sclerosis</keyword>
  <keyword>analgesic</keyword>
  <keyword>Central neuropathic pain related to multiple sclerosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Neuralgia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dronabinol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

